Phase : Measurable disease meeting the following criteria:
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study.
Significant organ dysfunction, not meeting inclusion criteria
Any patient not meeting institutional standard guidelines for transplant eligibility
Meeting the criteria for symptomatic multiple myeloma (hypercalcemia renal [kidney] impairment, anemia, bone lesions \[CRAB] criteria) before the initiation of systemic chemotherapy
Patients for whom a plan meeting institutional quality criteria cannot be designed for SBRT treatment via the MRI-guided teletherapy unit, but for whom an SBRT plan meeting institutional quality criteria can be designed for a conventional linear accelerator
Unilateral or bilateral disease meeting study criteria
Donor meeting  of the following criteria:
Any patient not meeting the eligibility criteria
The presence of measurable disease meeting the following criteria:
Meeting the protocol definition of TNmCRC assessed in the screening blood test.
Multiple myeloma meeting the following criteria:
Active disease meeting at least  of the following IWCLL  criteria for requiring treatment:
Disease-related: meeting one of the following diagnosis
Active disease meeting ?  of the following IWCLL  criteria for requiring treatment
Active disease meeting ?  of the following IWCLL  criteria for requiring treatment.
Measurable disease based on investigator's assessments meeting the following criteria:
Must have documented progressive disease by meeting at least one of the Prostate Cancer Working Group  Criteria
Positive serology for HTLV  or . Furthermore and prior to lymphodepleting chemotherapy, a subject meeting the following criteria is not eligible for participation in the study:
Patients must have progressive mCRPC defined by meeting at least one of the following criteria:
At least one measurable target lesion according to mRECIST meeting the following criteria:
Subject is ineligible for intensive induction chemotherapy by meeting at least  of the following criteria:
Subjects have active disease meeting the IWCLL  published criteria.
Presence of measurable disease meeting the following criteria:
Has, at screening, serologic laboratory tests meeting one or more of the following criteria:
Has, at screening, safety laboratory tests meeting one or more of the following criteria:
mTNBC (confirmed from most recent tissue sample) meeting the following criteria:
Presence of measurable disease meeting the following criteria:
Cardiac or peripheral vascular disease meeting any of the following criteria:
Patient must have an advanced stage malignancy defined as meeting at least one of the following criteria:
Measurable multiple myeloma disease, defined as meeting at least one of the following criteria within  days prior to first dose of study drug:
They are ineligible by virtue of meeting any exclusion criteria listed above
Laboratory values meeting the following criteria:
Presence of measurable disease meeting the following criteria:
Radiologically measurable disease meeting the following criteria:
Completed primary treatment (surgery, chemotherapy, and/or radiation) at minimum - weeks before the first group meeting, and maximum  months before the first group meeting, which approximates the re-entry phase of cancer survivorship.
Providing the majority of the informal (unpaid) care during RT for a patient meeting inclusion criteria
Multiple myeloma meeting the following criteria:
Participants who were eligible for the main trial with the exception of not meeting BMI criteria for obesity
Part , Expansion: Participants must have measurable disease meeting the following criteria: i. Subjects with HCC: At least  measurable target lesion according to mRECIST
Measurable disease meeting the following criteria and confirmed by central radiographic review:
